GLP-1 TV
GLP-1 Drugs Are About to Destroy Medicare Costs
Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
According to the video, Medicare will begin covering weight loss drugs such as Wegovy and Zepbound in July 2026 through a temporary route, and the speaker argues this could change the math behind Medicare premiums. He says he is not claiming Medicare will go bankrupt or that coverage will vanish. His point is that these drugs create a cost problem insurers have not faced before.
Published by The Retirement Nerds on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
The speaker explains the policy background: a 2003 law bars Part D from covering drugs prescribed only for weight loss, a Biden administration proposal to expand coverage was not finalized in April 2025, and CMS then created the balance model in December 2025 under demonstration authority. He says a bridge program will cover these drugs for weight loss at a $50 per month copay for people who meet clinical criteria and get prior authorization. According to the video, the bridge now runs through the end of 2027 because many Part D plan insurers declined to opt in to the balance model. He puts the negotiated Medicare price at $245 per month and cites an estimate that up to 13.7 million beneficiaries could eventually be eligible.
The speaker says a JAMA Health Forum projection showed $65.9 billion in drug costs over 10 years, $18.2 billion in savings, and a $47.7 billion net cost. He says that cost lands in Part B premiums, Part D premiums, or taxpayer funding. He then walks through Medicare Advantage, original Medicare with a stand-alone Part D plan, and Medigap, and closes by asking whether the system can afford success at scale.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:00 The speaker says Medicare will begin covering Wegovy and Zepbound for weight loss in July 2026, and that this may affect how premiums are calculated.
- 0:01 He explains that the 2003 law bars Part D from covering weight-loss-only drugs, so CMS is using a pilot-style demonstration authority instead.
- 0:02 According to the video, the bridge program offers a $50 per month copay with prior authorization and now runs through the end of 2027.
- 0:04 He argues weight loss drugs are moderately expensive, chronic and mass market, at $245 per month at the negotiated Medicare price.
- 0:05 He cites a JAMA Health Forum projection of a $47.7 billion net 10-year cost and says it would show up in Part B, Part D, or taxpayer funding.
- 0:07 The speaker describes how Medicare Advantage, original Medicare with Part D, and Medigap could each be affected differently.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Wegovy and Zepbound
Questions this video answers
When will Medicare cover Wegovy and Zepbound for weight loss?
According to the video, the Medicare GLP-1 bridge program starts in July 2026. It covers drugs like Wegovy and Zepbound for weight loss at a $50 per month copay for beneficiaries who meet clinical criteria, including prior authorization from a doctor.
How long does the Medicare GLP-1 bridge program last?
The speaker says the bridge runs through the end of 2027. He explains it was first meant to end December 31, 2026, but was extended because many Part D plan insurers did not opt in to the balance model.
Will Medicare GLP-1 coverage raise premiums for people who don't take the drugs?
The speaker says the exact amount is unknown. He argues that added Medicare spending shows up in Part B premiums, Part D premiums, or taxpayer funding, so people in the pool help pay whether or not they take the drugs.
How might GLP-1 coverage affect Medigap plans?
According to the video, Medigap premiums are not directly affected by drug costs because Medigap does not cover prescriptions. The speaker says that if the drugs reduce hospitalizations over time, rates could eventually stabilize, but he calls that a theory and not a guarantee.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
The GLP-1 Program Medicare Headlines Are MissingAccording to the video, many people believe Ozempic will cost $50 a month on Medicare starting this July.- What a GLP-1 costs at every program we trackToday’s lowest is $39/mo. Every program ranked by price alone. Compounded drugs are not FDA-approved.
Medicare Finally Covers Weight Loss Meds —Weight Loss Doctor Explains The GLP-1 Bridge ProgramThe speaker, who describes herself as a board-certified internal medicine and obesity medicine doctor, explains a new Medicare program called the Medicare GLP1 bridge.
Medicare Will Now Cover Weight Loss Drugs for $50 — But There's a CatchAccording to the video, CMS has announced a temporary Medicare GLP-1 Bridge program scheduled to start July 1, 2026 and expected to run through December 31, 2027.
$50 GLP-1s? Here’s How the Medicare Bridge WorksThe speaker of the channel gives a plain-language overview of the Medicare GLP-1 Bridge Short-Term Demonstration.
The $50 Medicare Zepbound, Wegovy Rumor! What's Actually Happening?The speaker of the channel the channel says that, as of March 8, 2026, there are no $50 per month Zepbound or Wegovy prescriptions available through Medicare for obesity.
✨NEW✨ SHOCKING insurance coverage for Zepbound/Wegovy?! New 2025 studyThe speaker covers a JP Morgan employer survey that, according to her, focused on GLP-1 coverage for the first time this year.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Does Medicare cover GLP-1s? Ozempic, Wegovy and Zepbound, route by route
Yes, by two different routes. Medicare drug plans (Part D, including Medicare Advantage plans with drug coverage) cover Ozempic and Mounjaro for type 2 diabetes. For weight loss, the Medicare GLP-1 Bridge covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay from 1 July 2026 to 31 December 2027, if you meet CMS's BMI criteria. The catch: the Bridge runs outside Part D, so that $50 never counts toward your deductible or out-of-pocket cap.
- GLP-1 patient assistance programs: what Lilly Cares and Novo's PAP actually cover
Both makers run free-drug programs for people with low income and no insurance or Medicare, but neither covers its weight-loss GLP-1. Novo Nordisk's Patient Assistance Program supplies Ozempic injections free to uninsured patients at or below 200% of the federal poverty level, and lists no Wegovy and no pills. Lilly Cares lists Trulicity as its only GLP-1: no Mounjaro, no Zepbound, no Foundayo. For weight loss, the realistic low-cost routes are the Medicare GLP-1 Bridge at $50 a month and the cash market.
- Does Medicaid cover GLP-1s? It depends which state, and on why
For type 2 diabetes, effectively yes everywhere: state Medicaid programmes must cover FDA-approved drugs for medically accepted indications, so Ozempic and Mounjaro are covered for blood sugar, almost always behind prior authorisation. For obesity it is a patchwork. As of January 2026 only 13 state Medicaid programmes covered GLP-1s for weight under fee-for-service. That is changing: CMS's BALANCE model began rolling out to state Medicaid programmes on 1 May 2026, but joining is voluntary for each state, and Medicaid out-of-pocket costs stay limited to nominal amounts under federal law.
Next steps
Wegovy prices
Find more like it
Cost and insurance
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















